NYSE:MRKPharmaceuticals
Merck (MRK) Valuation: Assessing New Growth Prospects Following Key Pipeline Successes
If you have been watching Merck (MRK), the latest string of clinical trial victories may have you revisiting your assumptions about the stock. In just the past week, Merck reported strong Phase 3 results for its CAPVAXIVE vaccine in younger populations, a promising Phase 2 readout and new regulatory designation for ifinatamab deruxtecan in difficult-to-treat lung cancer, and fresh evidence backing its PCSK9 inhibitor enlicitide. Taken together, these wins signal serious momentum in some of...